What is BioIncept?
BioIncept, LLC is a clinical-stage biotechnology company dedicated to advancing regenerative medicine. Its core focus lies in the development of therapeutics and diagnostics leveraging the PreImplantation Factor (PIF) technology. The company's proprietary Synthetic PreImplantation Factor (sPIF) platform is designed to enhance IVF outcomes and address challenging conditions such as autoimmunity and neuro-regeneration. As a subsidiary of Prince Biotech, BioIncept is strategically positioned to innovate within reproductive health and tissue regeneration.
How much funding has BioIncept raised?
BioIncept has raised a total of $10.5M across 2 funding rounds:
Private Equity
$3.2M
Private Equity
$7.3M
Private Equity (2013): $3.2M, investors not publicly disclosed
Private Equity (2016): $7.3M, investors not publicly disclosed
What's next for BioIncept?
With the recent influx of major strategic investment, BioIncept is poised for accelerated growth and the expansion of its research and development initiatives. The company's focus on regenerative medicine and its proprietary sPIF platform suggest a strategic direction towards addressing unmet needs in complex medical conditions. Future developments are likely to center on clinical trial progression and the potential commercialization of its innovative therapies, further solidifying its position in the biotechnology landscape.
See full BioIncept company page
